Brexpiprazole is an atypical antipsychotic primarily used for the treatment of schizophrenia and as an adjunct therapy for major depressive disorder (MDD). It functions as a dopamine D2 receptor partial agonist, meaning it helps balance dopamine levels in the brain rather than completely blocking dopamine receptors like traditional antipsychotics. This mechanism allows for symptom relief with a lower risk of side effects such as extrapyramidal symptoms and tardive dyskinesia. Additionally, brexpiprazole exhibits high affinity for serotonin 5-HT1A and 5-HT2A receptors, contributing to its mood-stabilizing and antidepressant properties. By modulating both dopamine and serotonin activity, brexpiprazole improves cognitive function, reduces hallucinations and delusions, and enhances emotional stability, making it a versatile option for mental health treatment.

Described as a “serotonin–dopamine activity modulator” (SDAM), brexpiprazole is designed to provide a more balanced neurotransmitter effect compared to earlier antipsychotics. Its unique pharmacological profile helps in reducing agitation, anxiety, and depressive symptoms, making it beneficial for patients with both schizophrenia and mood disorders. Furthermore, it has been studied for potential use in treating Alzheimer’s-related agitation and post-traumatic stress disorder (PTSD). The drug is generally well-tolerated, with a lower likelihood of metabolic side effects like weight gain and diabetes compared to other atypical antipsychotics. However, some patients may experience mild sedation, akathisia, or dizziness, particularly during the initial stages of treatment. Despite these considerations, brexpiprazole represents an advanced option in psychiatric care, offering stabilization of mood, improved cognitive function, and a favorable side effect profile when used under proper medical supervision.

• Certificate of Analysis (COA)
• Method of Analysis (MOA)
• Route of Synthesis (ROS)
• Good Manufacturing Practice (GMP) Compliance
• International Organization for Standardization (ISO) Certification
• Open Drug Master File (OP-DMF)
• Stability Data & Reports

Pharmacopoeia	IN-HOUSE
CAS No.	913611-97-9
Formula	C25H27N3O2S
Molecular Weight	433.57

Brexpiprazole is an atypical antipsychotic primarily used for the treatment of schizophrenia and as an adjunct therapy for major depressive disorder (MDD). It functions as a dopamine D2 receptor partial agonist, meaning it helps balance dopamine levels in the brain rather than completely blocking dopamine receptors like traditional antipsychotics. This mechanism allows for symptom relief with a lower risk of side effects such as extrapyramidal symptoms and tardive dyskinesia. Additionally, brexpiprazole exhibits high affinity for serotonin 5-HT1A and 5-HT2A receptors, contributing to its mood-stabilizing and antidepressant properties. By modulating both dopamine and serotonin activity, brexpiprazole improves cognitive function, reduces hallucinations and delusions, and enhances emotional stability, making it a versatile option for mental health treatment.

Described as a “serotonin–dopamine activity modulator” (SDAM), brexpiprazole is designed to provide a more balanced neurotransmitter effect compared to earlier antipsychotics. Its unique pharmacological profile helps in reducing agitation, anxiety, and depressive symptoms, making it beneficial for patients with both schizophrenia and mood disorders. Furthermore, it has been studied for potential use in treating Alzheimer’s-related agitation and post-traumatic stress disorder (PTSD). The drug is generally well-tolerated, with a lower likelihood of metabolic side effects like weight gain and diabetes compared to other atypical antipsychotics. However, some patients may experience mild sedation, akathisia, or dizziness, particularly during the initial stages of treatment. Despite these considerations, brexpiprazole represents an advanced option in psychiatric care, offering stabilization of mood, improved cognitive function, and a favorable side effect profile when used under proper medical supervision.

• Certificate of Analysis (COA)
• Method of Analysis (MOA)
• Route of Synthesis (ROS)
• Good Manufacturing Practice (GMP) Compliance
• International Organization for Standardization (ISO) Certification
• Open Drug Master File (OP-DMF)
• Stability Data & Reports

Pharmacopoeia	IN-HOUSE
CAS No.	913611-97-9
Formula	C25H27N3O2S
Molecular Weight	433.57